DIRECT DIAL: 212.451.2234
|June 10, 2021|
VIA EMAIL AND EDGAR
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
|Attention:||Abby Adams and Tim Buchmiller|
|Division of Corporation Finance,|
|Office of Life Sciences|
|Re:||Alzamend Neuro, Inc.|
Registration Statement on Form S-1 (No. 333-255955)
Registration Statement on Form 8-A (No. 001- )
Ladies and Gentlemen:
This letter will serve to withdraw the request for acceleration made yesterday by our client Alzamend Neuro, Inc.
Alzamend Neuro intends to seek acceleration of effectiveness of the above-referenced Registration Statements to 4:00 p.m., Eastern time, on Monday, June 14, 2021, or as soon as possible thereafter, and is re-submitting its request later this afternoon.
Thank you for your assistance.
|Very truly yours,|
|Spencer G. Feldman|
|cc:||Mr. Stephan Jackman|
Henry C.W. Nisser, Esq.